News

American Kratom Association Applauds FDA Crackdown on Dangerous Chemically Manipulated 7-OH, Pseudoindoxyl and 'M' Products
Synthetic products posing as kratom mislead and endanger consumers; AKA urges FDA to take decisive action against violative ...
US FDA to revise label of ADHD stimulants to add weight loss risk in patients younger than 6
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants to treat ...
Stocktwits on MSN17h
FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning
U.S health officials are updating the prescribing labels of long-acting ADHD medications to carry new warnings for children ...
MPR1h
FDA Approves Updated Label for Amyloid PET Imaging Agent Amyvid
The Food and Drug Administration (FDA) has approved an updated label for Amyvid (florbetapir F 18 injection) to support Alzheimer disease diagnosis in patients.
US FDA to revise ADHD stimulants labels to warn of weight loss risk in children under 6
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...
Olympus promises swift action after hardware blocked by FDA
Olympus is promising swift action to address concerns raised by the Food and Drug Administration (FDA) about some of its ...
CURE3h
Therapies Which Received FDA Approval in July: What Patients Should Know
Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...
GEN - Genetic Engineering and Biotechnology News1h
The Impact of FDA’s Animal Use Shift on the Future of Preclinical Testing
Traditional and new laboratory tools along with advances in AI are outlining a new paradigm in human disease modeling.
FDA approves Benlysta autoinjector for pediatric patients with active lupus nephritis
The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...
STAT1d
Many medical devices deemed ‘breakthrough’ by FDA are backed by patchy evidence
The FDA's breakthrough devices program helps the industry with faster review times, but the benefit to patients is unclear.
MPR5h
FDA: Weight Loss Risk in Younger ADHD Patients on Extended-Release Stimulants
Children younger than 6 years of age who are prescribed extended-release stimulants for attention-deficit hyperactivity disorder (ADHD) may experience ...
FDA announces sweeping changes to speed up the drug review process
An FDA pilot program, known as the Commissioner’s Priority Voucher program, could drastically change the way pharmaceutical ...